Abstract
Background The Center for Disease Control has estimated that over 24 million have been infected with COVID-19 in the US with over 6,700,000 being hospitalized, and over 1,174,000 deaths. Several other industrialized countries show similar numbers (CSSE, 2021). Chemical Intolerance (CI) is characterized by multi-system symptoms initiated by a one-time high dose or persistent low-dose exposure to environmental toxins including chemicals, foods and drugs. With an estimated 20% prevalence in the US, the symptoms of CI include fatigue, headache, weakness, rash, mood changes, musculoskeletal pain, gastrointestinal issues, difficulties with memory, concentration, and respiratory problems which are similar to COVID-19 and its sequelae. The purpose of this study was to determine if the pandemic had differential effects on those individuals with CI.
Methods A large U.S. population-based survey was launched involving 7,500 respondents asking if they ever had COVID-19, what the severity of it was, and if they have long COVID-19. Respondents were also assessed for CI using the Quick Environmental Exposure and Sensitivity Inventory (QEESI), a 50-item validated questionnaire designed to assess intolerances to inhaled chemicals, foods, and/or drugs. Respondents were classified as Low, Medium, or High CI.
Results Those in the High Chemical Intolerance class reported a greater COVID-19 prevalence, symptom severity, and long COVID-19 then in the Medium and Low CI classes (P<.0001). These associations were independent of race, ethnicity, income, age, and gender. However, there was significantly increased odds of COVID-19 severity among females and those over 45 years old. Asian individuals were least likely to have severe symptoms compared to White individuals (OR = 0.60). Black/African American individuals reported a lower prevalence of COVID-19 than Non-Hispanic Whites (NHW), but African American individuals with high CI reported 2.2 greater odds of reporting COVID-19 prevalence. Further, African American individuals had significantly greater odds of increased symptom severity.
Discussion Prior studies showed that higher risk for COVID-19-19 infection include the elderly, male sex, those with pre-existing comorbidities (e.g., challenged immunities) and those from minoritized racial/ethnic groups. The results of this study suggest that those with CI be included in a high risk group. Various risk subsets may exisit and future investigations could identify different risk subsets. Understanding these subgroups would be helpful in mounting targeted prevention efforts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by a grant from the Marilyn Brachman Hoffman Foundation, Fort Worth, TX, USA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research program was approved by the University of Texas Health Science Center at San Antonio Internal Research Board protocol number 20220246EX
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
